- Home
- AVIR vs CAPR Comparison
AVIR vs CAPR Comparison
Compare AVIR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- CAPR
- Stock Information
- Founded
- AVIR 2012
- CAPR 2005
- Country
- AVIR United States
- CAPR United States
- Employees
- AVIR N/A
- CAPR N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVIR Health Care
- CAPR Health Care
- Exchange
- AVIR Nasdaq
- CAPR Nasdaq
- Market Cap
- AVIR 290.4M
- CAPR 324.6M
- IPO Year
- AVIR 2020
- CAPR N/A
- Fundamental
- Price
- AVIR $3.37
- CAPR $6.74
- Analyst Decision
- AVIR Hold
- CAPR Strong Buy
- Analyst Count
- AVIR 1
- CAPR 8
- Target Price
- AVIR $6.00
- CAPR $24.75
- AVG Volume (30 Days)
- AVIR 306.9K
- CAPR 1.5M
- Earning Date
- AVIR 11-06-2025
- CAPR 08-11-2025
- Dividend Yield
- AVIR N/A
- CAPR N/A
- EPS Growth
- AVIR N/A
- CAPR N/A
- EPS
- AVIR N/A
- CAPR N/A
- Revenue
- AVIR N/A
- CAPR $13,392,150.00
- Revenue This Year
- AVIR N/A
- CAPR N/A
- Revenue Next Year
- AVIR N/A
- CAPR $6,061.53
- P/E Ratio
- AVIR N/A
- CAPR N/A
- Revenue Growth
- AVIR N/A
- CAPR N/A
- 52 Week Low
- AVIR $2.46
- CAPR $3.98
- 52 Week High
- AVIR $4.15
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- AVIR 42.27
- CAPR 45.28
- Support Level
- AVIR $3.35
- CAPR $5.68
- Resistance Level
- AVIR $3.86
- CAPR $6.43
- Average True Range (ATR)
- AVIR 0.13
- CAPR 0.42
- MACD
- AVIR -0.02
- CAPR -0.02
- Stochastic Oscillator
- AVIR 14.78
- CAPR 45.69
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.